However, these are restricted to few cancer entities and just a handful of examples exist, for instance EGFR inhibitors in non-small cell lung cancer tumors with EGFR mutations in exons 19/21 (afatinib, erlotinib, gefitinib) or resistance mutation T790 M (osimertinib), HER2 inhibitors (trastuzumab) in breast tumors with HER2 amplification/overexpression, and BCR-ABL inhibitors (bosutinib, desatinib, imatinib, nilotinib, ponatinib) in Philadelphia chromosome-positive hematologic malignancies [1]. This evidence concerns the gene ERBB2 and breast neoplasm.